- 2018 gastroesophageal reflux disease therapeutics market forecast: $4.9 billion
- All PPI GERD therapies to fall off-patent by 2018
- AstraZeneca and Eisai lead GERD market
LONDON--(BUSINESS WIRE)-- For the next eight years, the global market for gastroesophageal reflux disease (GERD) therapeutics is expected to decline by 2% CAGR, dropping from a 2010 valuation of $5.8 billion to $4.9 billion in 2018. According to a new report available from companiesandmarkets.com, the GERD market will be heavily impacted by patent expirations over the reporting period.
Gastroesophageal Reflux Disease (GERD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Over the next few years all GERD therapeutics falling into the Proton Pump Inhibitors, or PPI, category will drop off patent, such as Aciphex/Pariet (rabeprazole), and Nexium (esomeprazole). As generic alternatives erode the market share of the large pharmaceutical players, the market overall will also shrink, resulting in a 2018 forecast of just under $5 million – around $1 million down on the 2010 valuation.
Over the long term, the market will balance out, as the number of patients presenting to doctors with gastroesophageal reflux disease is increasing, and those already diagnosed require anti-reflux maintenance treatment.
Therapies used to treat GERD include: Aciphex (rabeprazole sodium), Dexilant (dexlansoprazole), Nexium (esomeprazole), Prevacid (lansoprazole), Prilosec (omeprazole), Protonix (pantoprazole sodium), Zegerid (omeprazole/sodium bicarbonate), Axid (nizatidine) and Pepcid (famotidine).
These products focus on reducing production of gastric acid; neutralizing gastric acidity, encourage/improve gastric emptying; restoring function of the lower esophageal sphincter and reducing the occurrence of transient lower esophageal sphincter relaxations (TLESRs).
The market is highly competitive with limited scope for new entrants. Safety and efficacy profiles of existing products are satisfactory, and the only real opportunities are for therapies for use by patients who respond inadequately to existing products.
The October 2011 GERD research piece includes over 71 pages of insight into the gastroesophageal reflux disease market, including statistics for the period 2010-2018. It provides comprehensive analysis of the 13 GERD therapeutic molecules under development in the product pipeline. Those products at an early stage of development have novel mechanisms of action and are focused on addressing the cause of GERD, as well as relief of symptoms such as achlorhydria (absent acid secretion).
Companies & Markets
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Pharmaceutical General Health